Briacell Therapeutics Corp

TSX:BCTCanadaView on NASDAQ

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Contact Information

Headquarters

Suite 300 - Bellevue Centre 235 -15th StreetWEST VANCOUVER, BC, Canada V7T 2X1

Phone

604-921-1810

Fax

604-921-1898

Executives

Non-Executive Independent Chairman of the Board

Jamieson Bondarenko

President, Chief Executive Officer, Director

William Williams

Chief Financial Officer, Corporate Secretary

Gadi Levin

Chief Scientific Officer

Miguel Lopez-Lago

Chief Medical Officer

Giuseppe Del Priore